VivoSeq
Other

Sanfilippo Syndrome

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Sanfilippo Syndrome is an early-stage landscape with 1 program across 2 companies. The most active players are Jazz Pharmaceuticals, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Cannabidiol

Jazz Pharmaceuticals

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome
Recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Preclinical·NCT06333041·35 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)